HUP9903688A2 - Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására - Google Patents

Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására

Info

Publication number
HUP9903688A2
HUP9903688A2 HU9903688A HUP9903688A HUP9903688A2 HU P9903688 A2 HUP9903688 A2 HU P9903688A2 HU 9903688 A HU9903688 A HU 9903688A HU P9903688 A HUP9903688 A HU P9903688A HU P9903688 A2 HUP9903688 A2 HU P9903688A2
Authority
HU
Hungary
Prior art keywords
olanzapine
preparation
pharmaceutical compositions
treating autism
compositions treating
Prior art date
Application number
HU9903688A
Other languages
English (en)
Inventor
Charles M. Beasley
Gary D. Tollefson
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9903688A2 publication Critical patent/HUP9903688A2/hu
Publication of HUP9903688A3 publication Critical patent/HUP9903688A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Luminescent Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Transplanting Machines (AREA)

Abstract

A találmány eljárást nyújt az aűtisztikűs betegség és/vagy a szellemielmaradőttság kezelésére, ami abból áll, hőgy a kezelésre szőrűlóbeteg szervezetébe őlanzapinnak vagy gyógyászati szempőntbólalkalmazható sójának vagy szőlvátjának hatásős mennyiségét jűttatjákbe. ŕ
HU9903688A 1996-03-11 1996-12-04 Use of olanzapine for the preparation of pharmaceutical compositions treating autism HUP9903688A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11
PCT/US1996/019576 WO1997033585A1 (en) 1996-03-11 1996-12-04 Method for treating autism

Publications (2)

Publication Number Publication Date
HUP9903688A2 true HUP9903688A2 (hu) 2000-03-28
HUP9903688A3 HUP9903688A3 (en) 2001-12-28

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903688A HUP9903688A3 (en) 1996-03-11 1996-12-04 Use of olanzapine for the preparation of pharmaceutical compositions treating autism

Country Status (19)

Country Link
EP (1) EP0946179B1 (hu)
JP (1) JP2000506860A (hu)
KR (1) KR19990087715A (hu)
CN (1) CN1213970A (hu)
AT (1) ATE249832T1 (hu)
AU (1) AU709181B2 (hu)
BR (1) BR9612552A (hu)
CA (1) CA2248741A1 (hu)
CZ (1) CZ290498A3 (hu)
DE (1) DE69630055T2 (hu)
EA (1) EA000768B1 (hu)
ES (1) ES2206614T3 (hu)
HU (1) HUP9903688A3 (hu)
IL (1) IL126161A0 (hu)
NO (1) NO984197L (hu)
NZ (1) NZ324615A (hu)
PL (1) PL328948A1 (hu)
TR (1) TR199801798T2 (hu)
WO (1) WO1997033585A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530339A (ja) 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
JP2002530341A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． デスメチルオランザピン組成物及び方法
ATE253364T1 (de) * 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
WO2014018468A1 (en) 2012-07-22 2014-01-30 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
PT3058371T (pt) 2013-10-14 2021-07-26 Univ Indiana Res & Tech Corp Uso de acamprosato para modular a ativação de erk 1-2 em modelos animais de sxf e tea e indivíduos diagnosticados com sxf e tea
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
DE69630055T2 (de) 2004-06-03
CN1213970A (zh) 1999-04-14
WO1997033585A1 (en) 1997-09-18
KR19990087715A (ko) 1999-12-27
CZ290498A3 (cs) 1999-10-13
EA000768B1 (ru) 2000-04-24
BR9612552A (pt) 1999-07-20
EP0946179A4 (en) 2000-04-19
PL328948A1 (en) 1999-03-01
TR199801798T2 (xx) 1998-12-21
NZ324615A (en) 2000-08-25
CA2248741A1 (en) 1997-09-18
JP2000506860A (ja) 2000-06-06
ES2206614T3 (es) 2004-05-16
NO984197D0 (no) 1998-09-11
EA199800821A1 (ru) 1999-02-25
AU1150197A (en) 1997-10-01
EP0946179B1 (en) 2003-09-17
DE69630055D1 (de) 2003-10-23
AU709181B2 (en) 1999-08-26
HUP9903688A3 (en) 2001-12-28
ATE249832T1 (de) 2003-10-15
NO984197L (no) 1998-11-03
IL126161A0 (en) 1999-05-09
EP0946179A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
DE69535349D1 (de) Implantierbare aktive medizinische Vorrichtung mit Mittel zur Unterscheidung zwischen Ruhe- bzw. Aktivzustand des Patienten
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
HUP9904023A2 (hu) Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
KR950700726A (ko) 치료 또는 진단용 조성물, 그 제조방법 및 용도(composition for therapeutic or diagnostic use, process for its preparation and its use)
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE78168T1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DE3765916D1 (de) Sonde zur einfuehrung in den verdauungs- oder ausscheidungstrakt des menschlichen oder tierischen koerpers, insbesondere lithotriptor-sonde.
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
ATE57841T1 (de) Sonde zur einfuehrung in den verdauungs- oder ausscheidungstrakt des menschlichen oder tierischen koerpers, insbesondere lithotriptorsonde.
UA19596A (uk) Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією
WO1994016103A3 (en) Detection of synthetic oligonucleotides extracted from body fluids or tissues